A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’ trials
Authors:
- Xavier PaolettiXPXavier Paoletti
- Birgit GeoergerBGBirgit Geoerger
- François DozFDFrançois Doz
- André BaruchelABAndré Baruchel
- François LokiecFLFrançois Lokiec
- Christophe Le TourneauCTChristophe Le Tourneau
- 1 July 2013
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (10) , 2392-2402
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline frameworkContemporary Clinical Trials, 2012
- Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaEuropean Journal of Cancer, 2012
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in NeuroblastomaScience Translational Medicine, 2011
- Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in ChildrenClinical Cancer Research, 2011
- Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsNeuro-Oncology, 2010
- Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary EndpointJNCI: Journal of the National Cancer Institute, 2010
- Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agentsTargeted Oncology, 2010
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?British Journal of Cancer, 2009
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007